文献速递淋巴瘤

现代化疗时代基于风险及应答调整的早期结外鼻型NK/T细胞淋巴瘤治疗:中国淋巴瘤协作组研究

Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
PubMed 文献 · Am J Hematol · 2020-07-16

该回顾性研究纳入20家机构1360例接受放疗联合或不联合新方案化疗的早期结外鼻型NK/T细胞淋巴瘤患者,按列线图修正风险指数分层并行倾向性评分匹配分析。中高危患者加用新方案化疗较单纯放疗显著改善总生存和无进展生存,低危患者无获益。基于风险及应答调整的早期放疗联合化疗策略可行有效。

要点

  • 中高危患者放疗加新方案化疗较单纯放疗显著改善总生存(73.2% vs 60.9%)和无进展生存(63.5% vs 54.2%)。
  • 低危患者加用新方案化疗较单纯放疗未显著改善总生存和无进展生存。
  • 中高危患者放疗后化疗与化疗后放疗的总生存和无进展生存无显著差异。

核心结论

  • 在现代治疗时代,基于风险及应答调整的早期放疗联合化疗策略对中高危早期结外鼻型NK/T细胞淋巴瘤患者是可行且有效的策略。

研究设计与样本

  • 回顾性研究纳入20家机构1360例接受放疗联合或不联合新方案化疗的早期结外鼻型NK/T细胞淋巴瘤患者。
  • 患者接受单纯放疗、放疗后化疗或化疗后放疗,按列线图修正风险指数分层,并行倾向性评分匹配分析。

主要发现

  • 中高危患者放疗加新方案化疗较单纯放疗显著改善总生存(73.2% vs 60.9%,P < .001)和无进展生存(63.5% vs 54.2%,P < .001)。
  • 低危患者放疗加新方案化疗较单纯放疗未显著改善总生存和无进展生存。
  • 中高危患者放疗后化疗与化疗后放疗的总生存(77.7% vs 72.4%,P = .290)和无进展生存(67.1% vs 63.1%,P = .592)无显著差异。
  • 诱导化疗达完全缓解者,三周期内开始放疗与三周期后开始放疗的总生存(78.2% vs 81.7%,P = .915)和无进展生存(68.2% vs 69.9%,P = .519)相似。
  • 诱导化疗未达完全缓解者,早期放疗较晚期放疗的无进展生存更优(63.4% vs 47.6%,P = .019)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to determine the survival benefits of chemotherapy (CT) added to radiotherapy (RT) in different risk groups of patients with early-stage extranodal nasal-type NK/T-cell lymphoma (ENKTCL), and to investigate the risk of postponing RT based on induction CT responses. A total of 1360 patients who received RT with or without new-regimen CT from 20 institutions were retrospectively reviewed. The patients had received RT alone, RT followed by CT (RT + CT), or CT followed by RT (CT + RT). The patients were stratified into different risk groups using the nomogram-revised risk index (NRI). A comparative study was performed using propensity score-matched (PSM) analysis. Adding new-regimen CT to RT (vs RT alone) significantly improved overall survival (OS, 73.2% vs 60.9%, P < .001) and progression-free survival (PFS, 63.5% vs 54.2%, P < .001) for intermediate-risk/high-risk patients, but not for low-risk patients. For intermediate-risk/high-risk patients, RT + CT and CT + RT resulted in non-significantly different OS (77.7% vs 72.4%; P = .290) and PFS (67.1% vs 63.1%; P = .592). For patients with complete response (CR) after induction CT, initiation of RT within or beyond three cycles of CT resulted in similar OS (78.2% vs 81.7%, P = .915) and PFS (68.2% vs 69.9%, P = .519). For patients without CR, early RT resulted in better PFS (63.4% vs 47.6%, P = .019) than late RT. Risk-based, response-adapted therapy involving early RT combined with CT is a viable, effective strategy for intermediate-risk/high-risk early-stage patients with ENKTCL in the modern treatment era.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Qi SN, Yang Y, Zhang YJ, et al. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. Am J Hematol. 2020. PMID: 32449800. doi:10.1002/ajh.25878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。